Company intelligence / Profile preview

Orbigen

San Diego, California, USA

Ownership: Private
Development stage: Other

Overview

Orbigen was a San Diego-based biotechnology company that specialized in developing and commercializing innovative reagents for life science research. The company's product portfolio included a wide range of antibodies, recombinant proteins, and viral expression systems, with a particular emphasis on signal transduction and gene regulation. Orbigen was well-regarded for its lentiviral and retroviral expression technologies, as well as its RNA interference (RNAi) tools. In 2008, the company was acquired by OriGene Technologies, which integrated Orbigen's offerings into its broader catalog of gene-centric research tools.

Therapeutic areas: OncologyImmunology
Modalities: AntibodyRecombinant protein
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Orbigen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orbigen.

Explore the full profile